Happy New Year from Kaida BioPharma. Wishing you a prosperous 2025.
About us
Kaida BioPharma was founded on the research principles and clinical evidence of G129R, a growth hormone antagonist that has shown to induce programmed cell death (autophagy) in gynecologic tumors. Our collaboration with Dr. John Langenheim, professor at Thomas Jefferson University and Dr. Anil Sood at MD Anderson, who have published extensive research on G129R, has provided solutions we intend to bring to the clinic. At Kaida, we are dedicated to providing a new hope for patients with treatment-resistant gynecological cancers. Our mission is to develop innovative therapies that target the specific needs of those patients, offering a medical treatment that can make a significant difference. For more information, please visit kaida-biopharma.com.
- Website
-
https://www.kaida-biopharma.com/
External link for Kaida BioPharma
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Type
- Privately Held
Employees at Kaida BioPharma
-
Stella K. Vnook
Chief Executive Officer | Founder & President Biopharma Companies | Board Chair | Advisor | Mentor | Investor | Licensing | M&A | Strategy |…
-
Scott Kemps
Financial Advisor and investor / alternative portfolio strategies and private offerings of companies focused on clean energy and…
-
Craig Pierson
Founder/Investor/Advisor in Biotech & Medtech
Updates
-
#HappyHolidays from our family to yours! Wishing you a wonderful holiday season.
-
-
Our experienced leadership team is dedicated to driving meaningful change in #OvarianCancerResearch. Get to know the team here: https://bit.ly/3SagUwP #NoWomanLeftBehind #OvarianCancer #EndOvarianCancer
-
We are rapidly advancing toward our Phase 1 clinical study in #OvarianCancer. Follow along for more information as we continue to work to change the future for ovarian cancer patients. https://bit.ly/3SagUwP #NoWomanLeftBehind #OvarianCancerResearch #EndOvarianCancer
-
-
#OvarianCancer is often diagnosed at a late stage, making treatment challenging and costly. The patient journey can be incredibly difficult, and a solution is urgently needed to improve outcomes. https://bit.ly/3SagUwP #NoWomanLeftBehind #OvarianCancerResearch #EndOvarianCancer
-
-
Exploring new possibilities with our novel pipeline targeting #OvarianCancer, with the aim of providing innovative therapies that make a meaningful difference for patients. #OvarianCancerResearch #EndOvarianCancer #NoWomanLeftBehind
-
-
We are advancing targeted anti-cancer hormonal therapies to address the root cause of cancers affecting women. #OvarianCancerResearch #EndOvarianCancer #NoWomanLeftBehind #OvarianCancer
-
-
This #GivingTuesday, let’s keep giving hope by supporting National Ovarian Cancer Coalition. Please visit https://bit.ly/4ePWAcF to show your support and donate to this great cause. #OvarianCancerResearch #EndOvarianCancer #NoWomanLeftBehind #OvarianCancer
-
-
Our Mission: We are targeting the root cause of women’s cancers with next generation biologics. #OvarianCancerResearch #EndOvarianCancer #NoWomanLeftBehind
-
-
#OvarianCancer is the 2nd most common gynecologic cancer in the U.S. and causes more deaths than any other female reproductive cancer. This underscores the urgent need for awareness, research, and effective treatments. Learn more: https://bit.ly/4dOEVBz #NoWomanLeftBehind
-